$XBI $84.53 | -3.9%
Pipeline Updates
$HARP -27.4% Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
$CLSD +42.6% Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
$PFE +2.2% & $ARNA Pfizer Completes Acquisition of Arena Pharmaceuticals.
$CPRX -3.4% Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®.
$PTCT -2.9% PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference
$IMNM -8.0% FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19
$BBIO +0.1% bridgebio pharma, inc. to host investor call to discuss phase 2 data for limb-girdle muscular dystrophy type 2i (lgmd2i)
$AVDL +1.6% Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022
$EBS -7.7% Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
Business Updates
$TLSA 8.8% Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis
$HCM -7.5% Update on Status under Holding Foreign Companies Accountable Act
$ORPH -45.8% Commencement of in-court restructuring of Orphazyme A/S
Posted by DV/FS
Comments